Cover Image
市場調查報告書

Millennium Pharmaceuticals, Inc. - 產品平台分析

Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 251690
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
Millennium Pharmaceuticals, Inc. - 產品平台分析 Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日期: 2014年07月22日 內容資訊: 英文 96 Pages
簡介

Millennium Pharmaceuticals, Inc.是負責癌症治療藥的研究開發及商品化的生物製藥公司。主要產品Velcade (bortezomib) 是為了治療多發性骨髓瘤和復發性被套細胞淋巴瘤所開發的。該公司產品有15種以上以各種類型癌症為標的的腫瘤臨床實驗化合物。

本報告提供Millennium Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Millennium Pharmaceuticals, Inc.的基本資料

Millennium Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Millennium Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Millennium Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Millennium Pharmaceuticals, Inc.:開發中產品概況

Millennium Pharmaceuticals, Inc.

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 申請但不受理/被撤消的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Millennium Pharmaceuticals, Inc.:藥物簡介

  • bortezomib
  • alisertib
  • brentuximab vedotin
  • ixazomib citrate
  • MLN-0128
  • MLN-2480
  • orteronel
  • MLN-0264
  • MLN-1117
  • MLN-7243
  • pevonedistat hydrochloride
  • TAK-659
  • TAK-733
  • Small Molecules to Inhibit Histone Deacetylase 6 for Cacner

Millennium Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Millennium Pharmaceuticals, Inc.:最近的開發平台趨勢

Millennium Pharmaceuticals, Inc.:暫停中的計劃

Millennium Pharmaceuticals, Inc.:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • alisertib
    • betrixaban
    • bortezomib
    • HuL-2G7
    • orteronel
    • TAK-441
    • TAK-448
    • TAK-901
    • TAK-960
    • tandutinib

Millennium Pharmaceuticals, Inc.:企業發表

Millennium Pharmaceuticals, Inc.:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC05275CDB

Summary

Global Markets Direct's, 'Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Millennium Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Millennium Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Millennium Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Millennium Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Millennium Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Millennium Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Millennium Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Millennium Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Millennium Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Millennium Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Millennium Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Millennium Pharmaceuticals, Inc. Snapshot
    • Millennium Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Millennium Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Millennium Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
    • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Millennium Pharmaceuticals, Inc. - Pipeline Products Glance
    • Millennium Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Millennium Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Millennium Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Millennium Pharmaceuticals, Inc. - Drug Profiles
    • bortezomib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alisertib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brentuximab vedotin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixazomib citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-0128
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-2480
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • orteronel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-0264
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-1117
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-7243
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pevonedistat hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAK-659
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAK-733
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Histone Deacetylase 6 for Cacner
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Millennium Pharmaceuticals, Inc. - Pipeline Analysis
    • Millennium Pharmaceuticals, Inc. - Pipeline Products by Target
    • Millennium Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Millennium Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Millennium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Millennium Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Millennium Pharmaceuticals, Inc. - Dormant Projects
  • Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • alisertib
      • betrixaban
      • bortezomib
      • HuL-2G7
      • orteronel
      • TAK-441
      • TAK-448
      • TAK-901
      • TAK-960
      • tandutinib
  • Millennium Pharmaceuticals, Inc. - Company Statement
  • Millennium Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Millennium Pharmaceuticals, Inc., Key Information
  • Millennium Pharmaceuticals, Inc., Key Facts
  • Millennium Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Millennium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014
  • Millennium Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Millennium Pharmaceuticals, Inc. - Pre-Registration, 2014
  • Millennium Pharmaceuticals, Inc. - Filing rejected/Withdrawn, 2014
  • Millennium Pharmaceuticals, Inc. - Phase III, 2014
  • Millennium Pharmaceuticals, Inc. - Phase II, 2014
  • Millennium Pharmaceuticals, Inc. - Phase I, 2014
  • Millennium Pharmaceuticals, Inc. - Preclinical, 2014
  • Millennium Pharmaceuticals, Inc. - Discovery, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Millennium Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • Millennium Pharmaceuticals, Inc. - Dormant Developmental Projects,2014
  • Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014

List of Figures

  • Millennium Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Millennium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Millennium Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top